Biodexa Pharmaceuticals

Biodexa Pharmaceuticals is a Cardiff-based clinical-stage biopharmaceutical company advancing a pipeline of proprietary drug formulations for diseases with high unmet need.

Its lead programme, eRapa, an encapsulated oral formulation of rapamycin, is in a Phase 3 registrational trial for familial adenomatous polyposis, a rare inherited precancerous condition.

Additional programmes target rare brain cancers and type 1 diabetes. The company is supported by three proprietary drug delivery platforms addressing solubility, sustained release, and targeted delivery.